Physician profile
Marco A Araneda
NPI 1336181502
$5,599.51
in general payments reported to CMS, 2019-2025
57 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $640 · 2020: $218 · 2021: $201 · 2022: $1,064 · 2023: $1,322 · 2024: $1,129 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,970 · Education: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,969.79 |
| Education | $506.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $565.58 | 2021-2025 | Darzalex, Erleada, Tecvayli |
| Eisai INC. | $454.52 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $287.48 | 2019-2025 | |
| Pfizer INC. | $281.38 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $279.19 | 2019-2025 | Keytruda, Lynparza |
| Seagen INC. | $255.12 | 2020-2023 | Adcetris, Tukysa |
| Amgen INC. | $254.61 | 2019-2025 | Vectibix |
| Genentech USA, INC. | $218.40 | 2019-2025 | Polivy, Lunsumio, Tecentriq |
| Boston Scientific Corporation | $193.37 | 2024-2025 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial), Therasphere Y90 Glass Microspheres 10 Gbq |
| Astellas Pharma US INC | $193.25 | 2019-2025 | Xospata, Vyloy, Xtandi |
| Celgene Corporation | $189.81 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $172.95 | 2019-2025 | Opdivo, Opdualag |
| Glaxosmithkline, LLC. | $124.65 | 2022-2025 | Ojjaara, Blenrep |
| Smith+Nephew, INC. | $114.04 | 2023-2025 | Grafix Pl, Stravix, Oasis |
| Astrazeneca Pharmaceuticals LP | $108.78 | 2023 | Imfinzi |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marco Araneda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.